TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24460796

Group type: EXPERIMENTAL
Intervention: ER-treated injuries
Number of subjects: 4819

Group type: COMPARATOR
Intervention: Non-ER treated injuries
Number of subjects: 4819

Group type: COMPARATOR
Intervention: Not treated injuries
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Aged 18 to 30 years (ER-treated)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Blacks (ER-treated)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Hispanics (ER-treated)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Positive RAPS4 (ER-treated)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Motor vehicle injuries (ER-treated)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Cutting/piercing injuries (ER-treated)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Positive RAPS4 (general population)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Motor vehicle injuries (general population)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Cutting/piercing injuries (general population)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Blacks (general population)
Number of subjects: 4819

Group type: EXPERIMENTAL
Intervention: Hispanics (general population)
Number of subjects: 4819
Study: 22587850

Group type: EXPERIMENTAL
Intervention: Tai chi once a week (TC1)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Tai chi twice a week (TC2)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Low-level exercise program (LLE)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: All groups (TC1, TC2, LLE)
Number of subjects: 684
Study: 20617220

Group type: EXPERIMENTAL
Intervention: Conventional loading protocol
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Early loading protocol
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 12-week loading protocol
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 6-week loading protocol
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Roughened implant surfaces
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Attachment systems
Number of subjects: 106

Group type: COMPARATOR
Intervention: Overall success rate
Number of subjects: 106
Study: 18349537

Group type: EXPERIMENTAL
Intervention: MRA
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: TCD
Number of subjects: 97

Group type: COMPARATOR
Intervention: iaDSA
Number of subjects: 97
Study: 15995958

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 192
Study: 12606165

Group type: EXPERIMENTAL
Intervention: 10 mg Cu/l solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: <0.01 mg Cu/l solution (control)
Number of subjects: 30
Study: 10194774

Group type: EXPERIMENTAL
Intervention: Quantitative image analysis technique for the assessment of axonal injury using beta-amyloid precursor protein immunocytochemistry.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Semi-quantitative grading systems for determining the relationship between the extent of DAI and clinical features.
Number of subjects: 15
Study: 7755076

Group type: EXPERIMENTAL
Intervention: Intravenous saline solution containing a multivitamin preparation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched controls (nonvomiting pregnant women)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patients with longer duration of vomiting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen
Number of subjects: 20
Study: 2159860

Group type: EXPERIMENTAL
Intervention: 360 mg gamma-linolenic acid
Number of subjects: 22

Group type: COMPARATOR
Intervention: Indistinguishable placebo capsules
Number of subjects: 22
Study: 339932

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg and 100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxprenolol (80 mg)
Number of subjects: 10
Study: 31699211

Group type: COMPARATOR
Intervention: Varenicline tartrate (reference)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Varenicline oxalate (test)
Number of subjects: 30
Study: 29198872

Group type: EXPERIMENTAL
Intervention: ACB single injection with IV Dex 8 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: ACB single injection without IV Dex
Number of subjects: 177

Group type: COMPARATOR
Intervention: ACB catheter technique
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 177
Study: 27225334

Group type: EXPERIMENTAL
Intervention: Omarigliptin
Number of subjects: 0
Study: 24720686

Group type: EXPERIMENTAL
Intervention: Prevention Practitioner (PP) intervention
Number of subjects: 0
Study: 22800401

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment for 6 months
Number of subjects: 14
Study: 20573236

Group type: EXPERIMENTAL
Intervention: Family Links Nurturing Programme (FLNP)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 288
Study: 17587389

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Quinapril (20 mg)
Number of subjects: 41
Study: 16095548

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESIs) with local anaesthetic
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo (normal saline injection)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESIs)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: One ESI
Number of subjects: 228
Study: 12189359

Group type: EXPERIMENTAL
Intervention: Nelfinavir 1250 mg twice a day plus low doses of ritonavir (100 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nelfinavir 1250 mg twice a day plus low doses of ritonavir (200 mg)
Number of subjects: 24
Study: 10484575

Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 7547368

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy withdrawal
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy with anticoagulant therapy
Number of subjects: 112
Study: 1953230

Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuation of various conventional antirheumatic drugs
Number of subjects: 28
Study: 7284971

Group type: EXPERIMENTAL
Intervention: Moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: High-dose (6000 rads) radiation + 5-fluorouracil (5-FU)
Number of subjects: 194

Group type: COMPARATOR
Intervention: High-dose (6000 rads) radiation alone
Number of subjects: 194
Study: 30740695

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) oral solution (Epidiolex; 100 mg/mL), titrated from 2.5 to 20 mg/kg/d over a 2-week titration period, with a mean modal dose of 23 mg/kg/d after a median treatment duration of 38 weeks.
Number of subjects: 366
Study: 28523476

Group type: EXPERIMENTAL
Intervention: Patient Navigator Program (PN)
Number of subjects: 1911

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 1911
Study: 27085323

Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel (nab-P) 125 mg/m² + Gemcitabine (Gem) 1000 mg/m²
Number of subjects: 861

Group type: COMPARATOR
Intervention: Gemcitabine (Gem) 1000 mg/m²
Number of subjects: 861
Study: 25129475

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with target-controlled infusion (TIVA-TCI)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Balanced inhalation anaesthesia (BAL)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic prostatectomy (RALP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Laparoscopic prostatectomy (LRP)
Number of subjects: 102
Study: 22198451

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 949

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 949
Study: 19692134

Group type: EXPERIMENTAL
Intervention: Continuation of glimepiride (CONT)
Number of subjects: 26
Study: 17683704

Group type: EXPERIMENTAL
Intervention: Intensive care of cardiovascular risk factors (CVRF) management
Number of subjects: 247

Group type: COMPARATOR
Intervention: Usual care according to National Health Service recommendations
Number of subjects: 247
Study: 15897583

Group type: EXPERIMENTAL
Intervention: Flaxseed muffin (25 g daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo muffin
Number of subjects: 32
Study: 12413616

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by misoprostol 800 microg vaginally on the same day
Number of subjects: 80
Study: 9593980

Group type: EXPERIMENTAL
Intervention: Generalised regression neural network (GRNN) analysis during Necker cube reversals
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Necker cube reversal condition
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Coherent MEG activity
Number of subjects: 9
Study: 8452271

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure maintained at 50 +/- 5 mm Hg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mean arterial pressure maintained at 60 +/- 5 mm Hg
Number of subjects: 40
Study: 2878457

Group type: EXPERIMENTAL
Intervention: 0.54 g/kg ethanol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.3 g/kg ethanol
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0 g/kg ethanol (control)
Number of subjects: 13
Study: 30741616

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 27232953

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right posterolateral cerebellum
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over the right posterolateral cerebellum
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 76
Study: 24670314

Group type: EXPERIMENTAL
Intervention: NMES intervention followed by conventional treatment (thermaltactile stimulation with intensive repetition of a dry-swallow task)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional treatment without NMES
Number of subjects: 26
Study: 22341079

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20% citric acid
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BioPure MTAD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SmearClear
Number of subjects: 45

Group type: COMPARATOR
Intervention: 3% NaOCl (control)
Number of subjects: 45
Study: 21034484

Group type: EXPERIMENTAL
Intervention: Histamine-2-receptor antagonists (H2RA)
Number of subjects: 2092

Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 2092
Study: 18326251

Group type: EXPERIMENTAL
Intervention: 1% lidocaine solution
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine solution
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no EA)
Number of subjects: 90
Study: 15716665

Group type: EXPERIMENTAL
Intervention: Low microparticle diet
Number of subjects: 83

Group type: COMPARATOR
Intervention: Normal microparticle diet
Number of subjects: 83
Study: 12410512

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (5-25 ml) for local anesthesia of the groin
Number of subjects: 126
Study: 10220626

Group type: EXPERIMENTAL
Intervention: Lidocaine (4 boluses of 50 mg each every 2 minutes, then an infusion of 3 mg/min for 12 hours, then 2 mg/min for 36 hours)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Meta-analysis of prophylactic lidocaine
Number of subjects: 903
Study: 7717812

Group type: EXPERIMENTAL
Intervention: Maximally flexed neck with pelvic stabilization through muscle contraction
Number of subjects: 30
Study: 2380510

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 62
Study: 7016629

Group type: EXPERIMENTAL
Intervention: Budesonide 0.025% ointment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Budesonide 0.01% ointment (maintenance treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Betamethasone-17-valerate 0.1% ointment
Number of subjects: 32
Study: 30810228

Group type: EXPERIMENTAL
Intervention: Finn Chamber technique
Number of subjects: 3119

Group type: COMPARATOR
Intervention: TRUE Test technique
Number of subjects: 3119
Study: 28030374

Group type: EXPERIMENTAL
Intervention: Patient-Centered Personal Health Record and Patient Portal Implementation Toolkit Plus (MyHealthPortal)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study: 25854593

Group type: EXPERIMENTAL
Intervention: Myoinositol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23723410

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anterior stromal puncture (ASP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both AMT and ASP
Number of subjects: 40
Study: 21840680

Group type: EXPERIMENTAL
Intervention: Pentacam Eye Scanner measurements of corneal elevation
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Country-specific thresholds
Number of subjects: 555
Study: 19562253

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of methylprednisolone pre-operatively
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 17415706

Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors (AChEIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory compounds (rofecoxib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sex steroid hormones (testosterone, estrogens)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioxidants (tocopherol)
Number of subjects: 0
Study: 15557906

Group type: EXPERIMENTAL
Intervention: Heparin-bonded Dacron (HBD)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE)
Number of subjects: 209
Study: 11274349

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine gum
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo gum
Number of subjects: 22
Study: 9779839

Group type: EXPERIMENTAL
Intervention: sulfasalazine (SASP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: penicillamine (PEN)
Number of subjects: 200
Study: 7575227

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 100
Study: 2626520

Group type: EXPERIMENTAL
Intervention: Oral fluphenazine (FLU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluphenazine decanoate (FD)
Number of subjects: 0
Study: 769555

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg every 6 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29991214

Group type: EXPERIMENTAL
Intervention: Sports therapy and recreation exercise program
Number of subjects: 208
Study: 28430785

Group type: EXPERIMENTAL
Intervention: Naftopidil 75 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 25413896

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 24094282

Group type: EXPERIMENTAL
Intervention: Negativity during couple interaction
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Low anxiety or little history of chronic arguing
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Elevated levels of anxiety or chronic arguing
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Low warmth in couple interaction
Number of subjects: 128
Study: 21353463

Group type: EXPERIMENTAL
Intervention: Unimanual task with typically developing children
Number of subjects: 37

Group type: COMPARATOR
Intervention: Children with CP in unimanual task
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bimanual task with CP children (more affected hand)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bimanual task with CP children (less affected hand)
Number of subjects: 37
Study: 19409858

Group type: EXPERIMENTAL
Intervention: GW406381 25 mg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: GW406381 50 mg
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 17876866

Group type: EXPERIMENTAL
Intervention: Bimosiamose disodium 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimosiamose disodium 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimosiamose disodium 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15497369

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (20,000 IU of beta-carotene, 400 IU alpha-tocopherol acetate, 500 mg ascorbic acid, 100 microg selenium, and 30 mg zinc)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 18
Study: 11476126

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 9784819

Group type: EXPERIMENTAL
Intervention: Insall proximal realignments or isolated lateral retinacular releases
Number of subjects: 16
Study: 7874152

Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) powdered food
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High glycemic index (GI) powdered food
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) breakfast cereal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High glycemic index (GI) breakfast cereal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All test meals (low-GI and high-GI)
Number of subjects: 6
Study: 3312397

Group type: EXPERIMENTAL
Intervention: 5‐HTP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30086256

Group type: EXPERIMENTAL
Intervention: Topical pentoxifylline (PTX) 5% ointment, applied twice daily for 14 days
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 28813696

Group type: EXPERIMENTAL
Intervention: Standardized home-based training program (6-week strength and functional home training)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care (delayed start of training)
Number of subjects: 34
Study: 26263797

Group type: EXPERIMENTAL
Intervention: 1:1 inspiratory to expiratory (I:E) ratio
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1:2 inspiratory to expiratory (I:E) ratio
Number of subjects: 26
Study: 22000423

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 100
Study: 21896944

Group type: EXPERIMENTAL
Intervention: Slow rate (SR) weight loss intervention (0.7% body weight per week)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fast rate (FR) weight loss intervention (1.4% body weight per week)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both groups (SR and FR)
Number of subjects: 23
Study: 19324483

Group type: EXPERIMENTAL
Intervention: Intravenous EPO administration
Number of subjects: 78

Group type: COMPARATOR
Intervention: Subcutaneous EPO administration
Number of subjects: 78
Study: 16964676

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg once daily for 48 weeks
Number of subjects: 224
Study: 14742619

Group type: EXPERIMENTAL
Intervention: Unilateral active stimulation (hf rTMS over LDLPC and sham lf rTMS over RDLPC)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral active stimulation (hf rTMS over LDLPC and lf rTMS over RDLPC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bilateral sham stimulation
Number of subjects: 41
Study: 11111818

Group type: EXPERIMENTAL
Intervention: Prosorba Immunoadsorption Column treatment (active treatment arm)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham treatment (apheresis only, control arm)
Number of subjects: 99
Study: 9616826

Group type: EXPERIMENTAL
Intervention: Pristinamycin (1 g bid for 10-14 days)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid (500 mg q.i.d. for 10-14 days)
Number of subjects: 180
Study: 1570887

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 12.5 mg hyperbaric 0.5% bupivacaine and postoperative immobilisation for either 6 or 24 hours.
Number of subjects: 202

Group type: COMPARATOR
Intervention: Postoperative immobilisation for either 6 or 24 hours.
Number of subjects: 202
Study: 2981129

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31706805

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 74
Study: 30677181

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal bracing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-osteoporotic medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29948863

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 921

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 921
Study: 26818733

Group type: EXPERIMENTAL
Intervention: Pregabalin in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in addition to usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24505249

Group type: EXPERIMENTAL
Intervention: Left ventricular mass (LVM) tertiles
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Residual renal function
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Phosphate binder therapy
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Previous kidney transplantation
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Interleukin‐6 (Il‐6), high‐sensitivity C‐reactive protein (hsCRP), hepcidin‐25, connective tissue growth factor (CTGF)
Number of subjects: 327
Study: 22523045

Group type: EXPERIMENTAL
Intervention: Background music with lyrics
Number of subjects: 102

Group type: COMPARATOR
Intervention: Background music without lyrics
Number of subjects: 102
Study: 18839400

Group type: EXPERIMENTAL
Intervention: Generalized Anxiety Disorder Severity Scale (GADSS) administered via telephone
Number of subjects: 223